Table 1

Histopathological and immunohistochemical data (median values and IQR (Q1–Q3)) before and after RTX or placebo therapy

 Placebo (n=9)RTX-treated (n=16)
BaselineWeek 12p ValueBaselineWeek 12p Value
Focus score1.63 (0.84–3.27)1.97 (1.47–2.88)0.6781.7 (0.87–2.5)1.19 (0.59–1.23)0.179
LELs/mm20.77 (0.38–1.05)1.11 (0.67–1.23)0.3100.48 (0.24–0.91)0.18 (0–0.42)0.011
GCs/mm20.06 (0–0.23)0.09 (0.03–0.15)0.7350.07 (0–0.28)0 (0–0.1)0.004
CD45 (%)15.2 (5.86–16.92)14.8 (5.2–28.06)0.3747.45 (1.85–22.35)3.96 (0.48–7.71)0.011
CD20+ cells/mm22709 (1469–4395)3664 (2256–7979)0.1731172 (389–5278)355 (51–743)0.001
CD3+ cells/mm2863 (359–1483)1712 (725–2878)0.953315 (124–2157)180 (91–570)0.535
  • GCs, germinal centres; LEL, lymphoepithelial lesions; RTX, rituximab.

  • Bold typeface indicates the group of patients (placebo or RTX treated) and time point (baseline or week 12). Bold italic typeface indicates statistically significant results.